Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $6.55

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has earned an average rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $6.55.

Several equities research analysts have issued reports on GDRX shares. UBS Group decreased their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Wells Fargo & Company decreased their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Truist Financial decreased their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. Finally, The Goldman Sachs Group decreased their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $4.09, for a total value of $43,668.93. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of GoodRx

Several institutional investors have recently added to or reduced their stakes in GDRX. National Bank of Canada FI raised its holdings in shares of GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after purchasing an additional 2,151 shares during the period. Citizens Financial Group Inc. RI bought a new stake in shares of GoodRx during the 1st quarter valued at about $44,000. RPO LLC bought a new stake in shares of GoodRx during the 4th quarter valued at about $52,000. Jump Financial LLC bought a new stake in shares of GoodRx during the 1st quarter valued at about $49,000. Finally, Versor Investments LP bought a new stake in shares of GoodRx during the 4th quarter valued at about $54,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Trading Up 2.1%

GDRX traded up $0.09 during trading on Friday, hitting $4.48. 1,123,446 shares of the company's stock were exchanged, compared to its average volume of 1,391,725. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 0.74. GoodRx has a 1 year low of $3.68 and a 1 year high of $9.26. The stock has a 50 day moving average price of $4.27 and a 200 day moving average price of $4.52. The firm has a market cap of $1.60 billion, a P/E ratio of 56.01, a price-to-earnings-growth ratio of 1.95 and a beta of 1.16.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The company had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. During the same period in the previous year, the firm earned $0.08 earnings per share. GoodRx's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.